143 related articles for article (PubMed ID: 18045055)
1. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.
Gunby RH; Sala E; Tartari CJ; Puttini M; Gambacorti-Passerini C; Mologni L
Anticancer Agents Med Chem; 2007 Nov; 7(6):594-611. PubMed ID: 18045055
[TBL] [Abstract][Full Text] [Related]
2. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
3. Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells.
Turner SD; Alexander DR
Leukemia; 2006 Apr; 20(4):572-82. PubMed ID: 16482213
[TBL] [Abstract][Full Text] [Related]
4. Receptor tyrosine kinase alterations in AML - biology and therapy.
Stirewalt DL; Meshinchi S
Cancer Treat Res; 2010; 145():85-108. PubMed ID: 20306247
[TBL] [Abstract][Full Text] [Related]
5. Fusion tyrosine kinases: a result and cause of genomic instability.
Penserga ET; Skorski T
Oncogene; 2007 Jan; 26(1):11-20. PubMed ID: 16785987
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase receptors as attractive targets of cancer therapy.
Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
[TBL] [Abstract][Full Text] [Related]
7. Receptor tyrosine kinases as target for anti-cancer therapy.
Brunelleschi S; Penengo L; Santoro MM; Gaudino G
Curr Pharm Des; 2002; 8(22):1959-72. PubMed ID: 12171522
[TBL] [Abstract][Full Text] [Related]
8. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
9. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
Matsumura I; Mizuki M; Kanakura Y
Cancer Sci; 2008 Mar; 99(3):479-85. PubMed ID: 18177485
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.
Charest A; Kheifets V; Park J; Lane K; McMahon K; Nutt CL; Housman D
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):916-21. PubMed ID: 12538861
[TBL] [Abstract][Full Text] [Related]
11. Understand the acquired resistance of RTK inhibitors by computational receptor tyrosine kinases network.
Tian Y; Ma Y; Wu S; Zhang T; Li Z; Wang G; Zhang J
Comput Biol Chem; 2018 Oct; 76():275-282. PubMed ID: 30099250
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.
Longati P; Comoglio PM; Bardelli A
Curr Drug Targets; 2001 Mar; 2(1):41-55. PubMed ID: 11465538
[TBL] [Abstract][Full Text] [Related]
13. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
14. Receptor tyrosine kinases in normal and malignant haematopoiesis.
Reilly JT
Blood Rev; 2003 Dec; 17(4):241-8. PubMed ID: 14556779
[TBL] [Abstract][Full Text] [Related]
15. Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy.
Shabani M; Hojjat-Farsangi M
Curr Drug Targets; 2016; 17(14):1687-1703. PubMed ID: 26424402
[TBL] [Abstract][Full Text] [Related]
16. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor.
Zhao M; Kiyoi H; Yamamoto Y; Ito M; Towatari M; Omura S; Kitamura T; Ueda R; Saito H; Naoe T
Leukemia; 2000 Mar; 14(3):374-8. PubMed ID: 10720129
[TBL] [Abstract][Full Text] [Related]
17. Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases.
García-Echeverría C; Fabbro D
Mini Rev Med Chem; 2004 Mar; 4(3):273-83. PubMed ID: 15032674
[TBL] [Abstract][Full Text] [Related]
18. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.
Porter AC; Vaillancourt RR
Oncogene; 1998 Sep; 17(11 Reviews):1343-52. PubMed ID: 9779982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
